x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Dr RR Baliga"s "Got Knowledge Doc" Podkast

Dr RR Baliga, MD, MBA

"Got Knowledge Doc" Podkast with Dr. RR Baliga The "Got Knowledge Doc" Podkast, hosted by Dr. Ragavendra R. Baliga, is a knowledge-driven platform designed for physicians and healthcare providers seeking to stay at the forefront of medical science and innovation. With a distinguished career in cardiovascular medicine and academic leadership, Dr. Baliga engages with leading experts to explore cutting-edge research, emerging technologies, and transformative insights in medicine and beyond. Each

science natural sciences

All Episodes

04:19

Light Pollution, Circadian Disruption, Cardiac...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/11/05

🌙 Bright Nights, Higher Heart Risk ❤️‍🩹 New findings in JAMA Network Open highlight that greater exposure to artificial light at night is associated with significantly increased risks of coronary artery disease, myocardial infarction, heart failure, atrial fibrillation, and stroke — independent of sleep duration, lifestyle factors, and genetics. 💡 Clinical takeaway: Protecting circadian rhythms is cardiovascular prevention. Darker nights = healthier hearts. 🛌 Simple steps: blackout

en

04:23

Rethinking Immune Aging: It Starts Sooner Than We...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/11/05

The immune clock starts earlier than we think ⏳🧬 A landmark Nature study shows that immune aging begins quietly in midlife — decades before clinical frailty. Using >16M single-cell profiles and longitudinal vaccine responses, researchers found: • Stable, early transcriptional drift in naïve & memory T cells • A subtle TH2 shift that may weaken antiviral antibody quality • Reduced IgG class-switching to repeat flu antigens (e.g., B/Phuket) • No acceleration from CMV infection despite

en

03:28

Seven Years Later: TAVR Didn't Blink 😎🫀

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/11/04

🫀 TAVR or SAVR? The 7-Year Truth New 7-year results from the PARTNER-3 trial (NEJM) show that in low-risk patients with severe symptomatic aortic stenosis, TAVR holds pace with surgery — delivering comparable survival, stroke rates, rehospitalization, valve durability, and quality-of-life outcomes. 🔎 Highlights • Composite events: 34.6% (TAVR) vs 37.2% (SAVR) • Mortality: 19.5% vs 16.8% • Valve failure: 6.9% vs 7.3% • Aortic gradients remain low in both groups 💡 Clinical rhythm: less AF

en

06:00

Dr RR Baliga's Philosophical Discourses: Baruch...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/11/04

🌿 Spinoza: Reason, Nature, Freedom Today's deck explores Baruch Spinoza — the quietly revolutionary Dutch philosopher who shaped rationalism, modern biblical criticism, and secular democracy. He saw God = Nature, championed intellectual freedom, and argued that understanding our emotions transforms them — not far from cognitive-behavioral ideas we use in modern medicine. His reminder feels timely: human flourishing grows where inquiry is free, passions are understood, and systems support

en

05:14

New Mitral Frontier 🚪🫀🚶‍♂️ TMVR Opens a Third Pathway

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/11/03

A new era for complex mitral regurgitation. The ENCIRCLE pivotal trial in The Lancet reports that fully percutaneous, transfemoral, transseptal TMVR (SAPIEN M3) achieved durable MR reduction (≈96% ≤1+ at 1 year), low early mortality, and meaningful improvement in symptoms and quality of life for patients unsuitable for surgery or TEER. A third pathway for mitral disease is emerging—one built on precision access, valve-in-valve durability planning, and advancing patient selection. Innovation

en

03:44

Immune Fountain of Youth? Mesenchymal Magic 💧✨

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/11/03

🧬 Can we rejuvenate the aging immune system? A remarkable Nature Biotechnology study shows that a rare population of periostin-positive mesenchymal niche cells can rebuild the adult thymus, recruit new T-cell progenitors, and restore immune responses after injury. By harnessing CCL19-expressing stromal support, the authors demonstrate a path toward immune renewal in aging, cancer therapy recovery, and HSCT survivors. ✨ A glimpse of regenerative immunology's future: Rebuild. Recruit

en

04:53

Cancer, Cure, Cardio-Care 🔬✅🫀 Not Every Survivor...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/11/02

🩺🎗️ Cardio-Oncology Insight: Not Every Breast Cancer Survivor Needs a Cardiologist As breast cancer survivorship grows, understanding who truly benefits from long-term cardiac follow-up becomes essential. An important editorial in JAMA Oncology underscores a key principle: risk-stratified care, not reflex surveillance. 👩‍⚕️🔍 Age and traditional cardiovascular risk factors outweigh treatment exposure (including anthracyclines and ERBB2 therapy) in driving late heart failure and cardiomyopathy

en

03:41

Urolithin A: The Immune Youth Serum? ✨🧫🧓➡️🧑‍⚕️

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/11/02

🧬 Can we rejuvenate the aging immune system? A new Nature Aging trial suggests we might be closer than we thought. In 50 healthy adults aged 45–70, urolithin A—a mitophagy activator—improved immune fitness over just 28 days: ✅ ↑ naïve CD8⁺ T cells ✅ ↓ exhaustion markers (TOX) ✅ ↑ mitochondrial biogenesis (PGC-1α) ✅ ↑ fatty-acid oxidation capacity ✅ ↑ NK cell and monocyte function ✅ ↑ bacterial phagocytosis 💊 Well-tolerated with minimal adverse events 🔬 This builds on compelling translational

en

03:49

Short DAPT Wins, Ultra-Short Fails 🚫1️⃣✅3️⃣...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/11/01

🫀 Personalizing DAPT: When "One Size Fits All" Fails 🕊️💊 The HOST-BR trial in The Lancet offers an important clinical lesson: Bleeding risk should guide antiplatelet duration after PCI — not habit, not inertia. 🔍 Key insight In ARC-HBR patients, 1-month DAPT was not non-inferior to 3 months In non-HBR patients, 3-month DAPT was non-inferior to 12 months and reduced bleeding 🧠 Clinical takeaway ➡️ Ultra-short (1-mo) DAPT is risky in high-bleeding-risk patients ➡️ Short (3-mo)

en

06:10

Beyond CPAP, Beyond Weight, 🛌💨✨: Sultiame Steps Into...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/11/01

🚨 New Pharmacotherapy for Obstructive Sleep Apnoea 🌙💊 In a landmark Phase 2 trial published in The Lancet, sultiame— a carbonic anhydrase inhibitor—showed dose-dependent reduction in AHI and improved nocturnal oxygenation in adults with moderate–severe OSA. 💡 Key insights: • 298 participants across 5 European countries • 200 mg daily delivered the best efficacy-to-tolerability balance • Benefits most notable in sleepy phenotypes (ESS >10) • Mild, dose-related paraesthesia most common AE 🔬 A

en

04:19

💊 Who Gets Aspirin? Risk Rules Rewritten!

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/10/31

📢 New Study Alert 🩺💊 In JAMA Internal Medicine, a national analysis reveals that using the PREVENT risk calculator (vs Pooled Cohort Equations) dramatically reduces the number of U.S. adults aged 40–59 eligible for aspirin in primary prevention of cardiovascular disease. Among 7.6 million current aspirin users, >96% wouldn't qualify by PREVENT 🤯. Time to rethink our calculators and consider deprescribing where net benefit is questionable. 📰 Read more:

en

04:14

🪙 Double Trouble or Dual Protection? 💊💊🛡️ Ticagrelor...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/10/30

🧠 TACSI Trial in NEJM (Sep 2025) challenges the status quo on dual antiplatelet therapy after CABG for ACS! 👨‍⚕️ 2201 patients across 5 Nordic countries 💊 Ticagrelor + Aspirin ≠ better outcomes vs Aspirin alone 📉 No reduction in death, MI, stroke, or revascularization 🩸 But bleeding (4.9% vs 2.0%) & dyspnea (18.2% vs 6.4%) increased 📚 Guidelines may need rethinking. 📖 Jeppsson A et al. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2508026 #TACSI #Cardiology #CABG #DAPT #ACS #NEJM

en

04:55

🎯 Early Aspirin Withdrawal After PCI in ACS is Risky?

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/10/29

🧪 NEO-MINDSET Trial 🇧🇷 published in NEJM asks: Can we safely drop aspirin early after PCI in acute coronary syndromes (ACS)? 💊 Monotherapy with ticagrelor/prasugrel reduced bleeding 🩸 but increased early ischemic events 💥 vs dual antiplatelet therapy (DAPT). ❗ Noninferiority for major adverse cardiovascular events was not met. 🔍 DAPT still stands tall in early post-PCI ACS care. Kudos to the Brazilian team for a landmark RCT! 📖 NEJM 2025 | doi: 10.1056/NEJMoa2507980 #NEOMINDSET #PCI

en

06:31

🧠 Precision, Prevention, Progress: Low-Dose Aspirin...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/10/29

🚨 New in NEJM — The ALASCCA Trial 🧬 Low-dose aspirin (160 mg/day) reduced colorectal cancer recurrence in patients with PIK3CA, PIK3R1, or PTEN mutations 🎯 ✅ 3-year recurrence: 7.7% (aspirin) vs 14–17% (placebo) ✅ Group A HR: 0.49 | Group B HR: 0.42 ✅ NNT as low as 6 in stage III rectal cancer 💥 ⚠️ Slight increase in adverse events 🧠 Editorial calls it a new standard of care: 🔬 Genotype early + 💊 Start aspirin early = 📉 Lower recurrence 📖 Read both the trial and editorial in NEJM,

en

03:56

🏥 Modern PCI, 🫀 MI Managed, 💉 Aspirin Dropped Early,...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/10/28

💡 TARGET-FIRST trial (NEJM, Aug 2025) shows that in low-risk AMI patients post-PCI with complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy is noninferior to dual antiplatelet therapy—with 54% fewer bleeding events 🩸🛑💊 ⚖️ A modern, patient-tailored antiplatelet strategy—backed by potent P2Y12 inhibitors and smart selection—might just be the new norm in contemporary cardiology 🫀 📘 New England Journal of Medicine 🔗

en

04:36

Dr RR Baliga's Philosophical Discourses: René...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/10/28

💡 "Cogito, ergo sum" — I think, therefore I am. René Descartes laid the foundation of modern Western philosophy and scientific reasoning, linking algebra to geometry, and mind to body. 🧠📐 His legacy reminds healthcare professionals to unite reason with compassion — science with soul. ❤️⚕️

en

04:23

1. 💔🩸⚖️ Aspirin, Anticoagulants & Harm: Rethinking...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/10/27

💊🫀 Aspirin in the Crosshairs? The AQUATIC Trial (NEJM, Aug 2025) raises sharp questions on dual-pathway therapy in chronic coronary syndrome (CCS) patients already on long-term anticoagulation. 📉 Adding aspirin led to: • ↑ Ischemic events (HR 1.53; P=0.02) • ↑ Mortality (HR 1.72; P=0.01) • ↑ Major bleeding (HR 3.35; P<0.001) 🧠 Takeaway: More isn't always better. In high-risk CCS, aspirin may harm more than help. 📚 Read: https://www.nejm.org/doi/full/10.1056/NEJMoa2507532 #Cardiology

en

03:13

🦧💥🧠 Lead, Language & Legacy: How Lead Shaped Human...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/10/27

🧠💥 Could lead poisoning have helped shape human evolution? A bold new hypothesis suggests that Homo sapiens may have survived while Neanderthals and Denisovans vanished—thanks to genetic defenses against environmental lead. 🧬 By analyzing fossil teeth 🦷 and testing brain organoids 🧪, researchers found that ancient lead exposure disrupted key language-related genes (like FOXP2)—but not in modern human variants. 👣 Sometimes, evolution turns adversity into advantage. 📖 Published in Science

en

03:46

🧬 How HMGN1 Gene Hijacks the Heart in Trisomy 21...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/10/26

🚨 New in Nature 🧬: Groundbreaking study reveals how HMGN1, a dosage-sensitive epigenetic regulator on chromosome 21, reprograms atrioventricular cardiomyocytes into a ventricular fate—driving congenital heart defects in Down syndrome 💔🫀. Using hiPSCs, single-cell RNA sequencing, and a CRISPRa CROP-seq screen, researchers pinpoint HMGN1 as a causal gene. Strikingly, reducing its dosage in a trisomy 21 mouse model reversed ventricular septal defects (VSDs) 🔧🐭. This is a model for dissecting

en

05:28

🧯 No Smoke, Still Fire – Rethinking Lung Cancer in...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/10/26

🚭 Lung Cancer in Nonsmokers – a hidden epidemic affecting up to 20% of global cases 🌍. Unlike tobacco-related disease, this form often strikes younger, female, and Asian populations, with EGFR and ALK mutations driving tumors 🔬. Despite low mutation burden and no smoking history, these patients benefit immensely from targeted therapies like osimertinib and lorlatinib 🎯. Yet, there’s no USPSTF recommendation for screening in this group 😔. We must push for awareness, early detection, and

en

767 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter